​

Kymera Therapeutics (KYMR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KYMR Stock Forecast

Kymera Therapeutics (KYMR) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $57.00, with a high of $60.00 and a low of $54.00. This represents a 20.53% increase from the last price of $47.29.

$25 $32 $39 $46 $53 $60 High: $60 Avg: $57 Low: $54 Last Closed Price: $47.29

KYMR Stock Rating

Kymera Therapeutics stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (85.71%), 3 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 0 3 18 Strong Sell Sell Hold Buy Strong Buy

KYMR Price Target Upside V Benchmarks

TypeNameUpside
StockKymera Therapeutics20.53%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts118
Avg Price Target$60.00$60.00$56.63
Last Closing Price$47.29$47.29$47.29
Upside/Downside26.88%26.88%19.75%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 253143--20
May, 253133--19
Apr, 253143--20
Mar, 253134--20
Feb, 253134--20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 03, 2025Michael SchmidtGuggenheim$60.00$43.5837.68%26.88%
Feb 28, 2025H.C. Wainwright$54.00$31.3572.25%14.19%
Dec 05, 2024Etzer DaroutBMO Capital$55.00$44.0824.77%16.30%
Dec 02, 2024Derek ArchilaWells Fargo$57.00$48.5417.43%20.53%
Sep 27, 2024Jeff JonesOppenheimer$56.00$49.4713.20%18.42%
Aug 26, 2024Andy ChenWolfe Research$65.00$47.7836.04%37.45%
Aug 08, 2024Andrew FeinH.C. Wainwright$60.00$40.3148.85%26.88%
Jun 17, 2024Andrew FeinH.C. Wainwright$46.00$32.2942.46%-2.73%
May 23, 2024Edward TenthoffPiper Sandler$56.00$34.8460.73%18.42%
May 03, 2024Jeff JonesOppenheimer$52.00$36.3043.25%9.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 03, 2025GuggenheimBuyBuyhold
Jun 03, 2025B. RileyBuyupgrade
Jun 02, 2025Morgan StanleyEqual-WeightOverweightupgrade
Dec 05, 2024BMO CapitalMarket Performinitialise
Oct 31, 2024JefferiesBuyBuyhold
Sep 27, 2024Wolfe ResearchEqual-WeightEqual-Weighthold
Sep 27, 2024OppenheimerOutperformOutperformhold
Sep 09, 2024Wolfe ResearchBuyBuyhold
Aug 26, 2024Wolfe ResearchOutperformupgrade
Aug 14, 2024Morgan StanleyEqual-WeightEqual-Weighthold

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.53$-2.04$-2.82$-2.52$-2.98----
Avg Forecast$-1.44$-1.86$-2.90$-2.64$-2.82$-3.06$-3.54$-3.57$-2.90
High Forecast$-0.44$-0.57$-0.64$-1.81$-2.15$-1.42$-2.49$-2.30$-0.03
Low Forecast$-3.18$-4.13$-7.72$-3.11$-3.15$-4.14$-5.73$-4.68$-8.26
Surprise %75.69%9.68%-2.76%-4.55%5.67%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.03M$72.83M$46.83M$78.59M$47.07M----
Avg Forecast$42.01M$83.71M$50.19M$69.37M$53.87M$68.16M$63.62M$88.05M$181.58M
High Forecast$81.32M$162.04M$114.40M$118.35M$107.40M$170.65M$64.51M$89.94M$439.66M
Low Forecast$19.65M$39.15M$20.17M$39.77M$42.96M$18.28M$62.72M$86.16M$43.53M
Surprise %-18.99%-12.99%-6.70%13.30%-12.62%----

Net Income Forecast

$-500M $-400M $-300M $-200M $-100M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.95M$-98.00M$-151.83M$-146.96M$-223.86M----
Avg Forecast$-83.85M$-78.75M$-127.85M$-146.96M$-167.47M$-162.27M$-319.20M$-203.93M$-169.39M
High Forecast$-25.83M$-63.00M$-102.28M$-117.57M$-125.71M$-83.08M$-145.22M$-134.43M$-1.97M
Low Forecast$-185.85M$-94.50M$-153.42M$-176.35M$-184.14M$-241.47M$-334.37M$-273.43M$-482.36M
Surprise %-47.59%24.43%18.76%-33.67%----

KYMR Forecast FAQ

Is Kymera Therapeutics stock a buy?

Kymera Therapeutics stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kymera Therapeutics is a favorable investment for most analysts.

What is Kymera Therapeutics's price target?

Kymera Therapeutics's price target, set by 21 Wall Street analysts, averages $57 over the next 12 months. The price target range spans from $54 at the low end to $60 at the high end, suggesting a potential 20.53% change from the previous closing price of $47.29.

How does Kymera Therapeutics stock forecast compare to its benchmarks?

Kymera Therapeutics's stock forecast shows a 20.53% upside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Kymera Therapeutics over the past three months?

  • June 2025: 15.00% Strong Buy, 70.00% Buy, 15.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 15.79% Strong Buy, 68.42% Buy, 15.79% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 15.00% Strong Buy, 70.00% Buy, 15.00% Hold, 0% Sell, 0% Strong Sell.

What is Kymera Therapeutics’s EPS forecast?

Kymera Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.06, marking a 2.68% increase from the reported $-2.98 in 2024. Estimates for the following years are $-3.54 in 2026, $-3.57 in 2027, and $-2.9 in 2028.

What is Kymera Therapeutics’s revenue forecast?

Kymera Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $68.16M, reflecting a 44.81% increase from the reported $47.07M in 2024. The forecast for 2026 is $63.62M, followed by $88.05M for 2027, and $181.58M for 2028.

What is Kymera Therapeutics’s net income forecast?

Kymera Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-162M, representing a -27.51% decrease from the reported $-224M in 2024. Projections indicate $-319M in 2026, $-204M in 2027, and $-169M in 2028.